Nov 4, 4:12 PM ET
Progyny reported record third-quarter 2026 revenue of $341.3 million, up 8.9%, and net income of $26.3 million, or $0.32 per diluted share, versus $13.9 million, or $0.15, a year earlier. The company raised the midpoint of its full-year 2026 guidance ranges, which signals that management expects stronger results for the year.
- Q3 2026 net income was $26.3 million, or $0.32 per diluted share, versus $13.9 million, or $0.15, in Q3 2025.
- Q3 2026 Adjusted EBITDA was $58.4 million, up 6.3%, with a margin of 17.1% versus 17.5% a year earlier.
- Full-year 2026 revenue is projected at $1.365 billion to $1.385 billion, and net income at $107.0 million to $110.6 million.
- Nearly 11 million shares were repurchased in 2026 so far, with approximately $51 million remaining under the current authorization.
Read the filing on SEC.gov ↗
Aug 6, 4:10 PM ET
Progyny reported second-quarter 2026 revenue of $350.5 million, up 5.3% from $332.9 million, and net income of $28.1 million, or $0.34 per diluted share, versus $0.19 a year earlier. The company also issued third-quarter and full-year 2026 guidance and said it has repurchased 2 million shares under its May 2026 program, with about $142.5 million remaining under that authorization.
- Revenue was $350.5 million, up 5.3%; fertility benefit services revenue rose 7.6% to $230.2 million.
- Diluted EPS was $0.34 versus $0.19; adjusted EPS was $0.55 versus $0.48.
- Q3 2026 revenue is projected at $335.0 million to $345.0 million; full-year 2026 revenue at $1.360 billion to $1.385 billion.
- Operating cash flow was $50.4 million versus $55.5 million a year earlier; the company had no debt as of June 30, 2026.
Read the filing on SEC.gov ↗
May 7, 4:03 PM ET
Progyny reported first quarter 2026 revenue of $328.5 million, up 1.4%, and net income of $24.2 million, or $0.29 per diluted share, compared with $15.1 million, or $0.17, a year earlier. Adjusted EBITDA fell 2.1% to $56.6 million as the company made planned platform investments, and the company issued full-year 2026 guidance with revenue of $1.365 billion to $1.405 billion.
- Revenue was $328.5 million, up 1.4% from $324.0 million; excluding $31.3 million from a large client in the prior-year period, revenue rose 12.2%.
- Net income was $24.2 million, or $0.29 per diluted share, versus $15.1 million, or $0.17, in Q1 2025; Adjusted EBITDA was $56.6 million, down 2.1%.
- The November 2025 share repurchase program ($200 million authorization) is complete, with 8.8 million shares bought; the board expects a decision on a new program around the end of May.
- Full-year 2026 guidance: revenue of $1.365 billion to $1.405 billion, net income of $103.7 million to $112.3 million, and Adjusted EBITDA of $232.0 million to $244.0 million.
Read the filing on SEC.gov ↗
Feb 26, 4:05 PM ET
Progyny reported fourth-quarter 2025 revenue of $318.4 million, up 6.7%, and full-year revenue of $1,288.7 million, up 10%. Full-year diluted earnings per share rose to $0.65 from $0.57, and the company issued 2026 guidance for revenue of $1.355 billion to $1.405 billion and net income of $95.4 million to $106.1 million. The Q1 2026 revenue outlook of (1.6)% to 2.5% growth signals modest near-term growth.
- Q4 2025 revenue was $318.4 million, up from $298.4 million; a large client that did not renew contributed $35.9 million in Q4 2024 and none in Q4 2025.
- Full-year 2025 net income was $58.5 million, or $0.65 per diluted share, versus $54.3 million, or $0.57, in 2024.
- 2026 outlook: revenue of $1.355 billion to $1.405 billion and net income of $95.4 million to $106.1 million.
- Q1 2026 revenue is projected at $319.0 million to $332.0 million, growth of (1.6)% to 2.5%.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.